Skip to main content
All lobbying filings

HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)

HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) filed a Q4 termination report for GRIFOLS SHARED SERVICES NORTH AMERICA, INC. on January 20, 2026, reporting $80,000 in lobbying income.

Lobbying for GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Biopharmaceutical company

All filings by HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) · Everything GRIFOLS SHARED SERVICES NORTH AMERICA, INC. has reported

 Filing · LD-2 quarterly report Q4 termination
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Representation ended
Dec 31, 2025
The registrant reported terminating its work for this client.

Official filing document

 Lobbyists on this filing 3
  • CYBIL G. ROEHRENBECK
    Previously held: Legislative Counsel to Office of Representative Walter B. Jones (2006 - 2010); Office of Representative J.C. Watts (2002)
  • CHARLES GARRISON IV
    Previously held: Senior Counsel, Senate Judiciary Committee, Office of Senator Sheldon Whitehouse (2018-2021), Counsel, Senate Judiciary Committee, Office of Senator Sheldon Whitehouse
  • EDUARDO IVAN ZAPIEN
    Previously held: Chief of Staff to US Senator Robert Menendez 2003-2008; National Outreach Director for the House Democratic Caucus 2002-2003

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

Immigration

Issues related to immigration policy.

 Bills named in this filing 5
  • H.R. 1476
    PLASMA Act
  • S. 694
    PLASMA Act
  • H.R. 1143
    Medicare IVIG Access Enhancement Act of 2025
  • H.R. 2343
    John W. Walsh Alpha-1 Home Infusion Act of 2025
  • H.R. 2172
    Preserving Patient Access to Home Infusion Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem